Jon Zugazagoitia

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers

Edurne Arriola, Reyes Bernabé, Rosario García Campelo et al. · JCO Precision Oncology · 2023 · 41 citations · Full text

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Santiago Ponce, S. Cedrés, Charles Ricordel et al. · Journal for ImmunoTherapy of Cancer · 2023 · 29 citations · Full text

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients

M. Teresa Agulló-Ortuño, Inmaculada García‐Ruiz, C. Vanesa Díaz-García et al. · Cancer Chemotherapy and Pharmacology · 2019 · 28 citations

Prognostic Biomarkers, Potential Predictive Biomarkers, Medicine +9

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

Jon Zugazagoitia, Ana Gómez‐Rueda, Eloísa Jantus‐Lewintre et al. · Lung Cancer · 2019 · 25 citations

Oncology, Sequencing, Tumor Heterogeneity +9

Sotorasib plus carboplatin and pemetrexed in <i>KRAS</i> G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Bob T. Li, Jeffrey Clarke, Enriqueta Felip et al. · Journal of Clinical Oncology · 2024 · 15 citations

Oncology, Biochemistry, Codebreak 101 +13